Free Trial
ASX:IPD

ImpediMed (IPD) Stock Price, News & Analysis

ImpediMed logo

About ImpediMed Stock (ASX:IPD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.62 million shs
Average Volume
N/A
Market Capitalization
$103.31 million
P/E Ratio
N/A
Dividend Yield
3.28%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Receive IPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter.

IPD Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
ImpediMed Unaffected by New U.S. Tariffs
See More Headlines

IPD Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:IPD
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-102.5
Net Income
-$19.79 million
Net Margins
-191.78%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.32 million
Price / Cash Flow
1.60
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,020,000,000
Free Float
N/A
Market Cap
$103.31 million
Optionable
Not Optionable
Beta
2.86
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (ASX:IPD) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners